tbuckley/cabot-search huggingface dataset:
Mutations in the DNA-binding codons of TP53, which are associated with decreased expression of TRAILreceptor-2, predict for poor survival in diffuse large B-cell lymphoma
Authors: Ken H. Young, Dennis D. Weisenburger, Bhavana J. Dave, Lynette Smith, Warren Sanger, Javeed Iqbal, Elias Campo, Jan Delabie, Randy D. Gascoyne, German Ott, Lisa Rimsza, H. Konrad Müller-Hermelink, Elaine S. Jaffe, Andreas Rosenwald, Louis M. Staudt, Wing C. Chan, Timothy C. Greiner
Journal: Blood (2007)
Preoperative left ventricular function: Minimal requirement for successful late results of valve replacement for aortic regurgitation
Authors: Kazuhiro Taniguchi, Susumu Nakano, Hajime Hirose, Hikaru Matsuda, Ryouta Shirakura, Kei Sakai, Tomohide Kawamoto, Shigehiko Sakaki, Yasunaru Kawashima
Journal: Journal of the American College of Cardiology (1987)
Interleukin 2 Therapy for Disseminated Cancer
Authors: Abraham Mittelman
Journal: JAMA (1987)

<h3>To the Editor.—</h3> In the Dec 12 issue of<i>JAMA</i>, Lotze et al<sup>1</sup>described the National Cancer Institute's experience with high-dose recombinant interleukin 2 (IL-2) therapy without lymphokine-activated killer (LAK) cells in patients with advanced melanoma and colon and ovarian carcinoma. This trial demonstrated antitumor activity of recombinant IL-2 alone in patients with malignant melanoma, but it was associated with considerable toxicity. In the same issue, Dr Moertel<sup>2</sup>stated that IL-2 therapy as administered in these studies is associated with unacceptably severe toxicity and astronomical costs. These are not balanced by any persuasive evidence of true net therapeutic gain. This specific treatment approach would not seem to merit further application in the compassionate management of patients with cancer. He suggested that general use is not justified. We agree that recombinant IL-2-LAK therapy as practiced by Rosenberg et al<sup>3</sup>and as adopted by six other centers funded by
Abstract 3069: Radial flow microfluidic device for high-throughput affinity-based isolation of circulating tumor cells
Authors: Vasudha Murlidhar, Rishindra M. Reddy, Mina Zeinali, Svetlana Grabauskiene, Mostafa Ghannad-Rezaie, Max S. Wicha, Diane M. Simeone, Nithya Ramnath, Sunitha Nagrath
Journal: Cancer Research (2014)

Abstract Circulating tumor cells (CTCs) are believed to play an important role in metastasis, a process accounting for the majority of cancer-related deaths. They offer a non-invasive biopsy technique to study tumors and are shown to be useful prognostic indicators. Because of their rarity in the bloodstream, microfluidic isolation techniques are complex and time-consuming, and provide yields of CTCs insufficient or non-viable for studies other than enumeration. Additionally, due to the low processing speeds, the volumes of blood processed remain limited and can be a hindrance to obtaining higher yields of CTCs and their potential use as biomarkers of early diagnosis. Here we report a novel high throughput microfluidic technology, the OncoBean Chip, employing radial flow that introduces a varying shear profile across the device and enables efficient cell capture by affinity at high flow rates. The cell recovery from whole blood was validated with cancer cell lines H1650 and MCF7, and the OncoBean Chip achieved an efficiency &amp;gt;80% at a throughput of 10 mL/hr, a flow rate yet achieved only in physical size based separation techniques. A cell viability of 92.91% shows that the cells recovered at high throughput could still be used for downstream analysis. Clinical competence was demonstrated in blood specimens from breast, pancreatic and lung cancer patients. The OncoBean Chip thus holds potential applications in the diagnosis of early stage cancers, where the low numbers of CTCs could be enriched using this novel device. Citation Format: Vasudha Murlidhar, Rishindra M. Reddy, Mina Zeinali, Svetlana Grabauskiene, Mostafa Ghannad-Rezaie, Max S. Wicha, Diane M. Simeone, Nithya Ramnath, Sunitha Nagrath. Radial flow microfluidic device for high-throughput affinity-based isolation of circulating tumor cells. [abstract]. In: Proceedings of the 105th Annual Meeting of the American Association for Cancer Research; 2014 Apr 5-9; San Diego, CA. Philadelphia (PA): AACR; Cancer Res 2014;74(19 Suppl):Abstract nr 3069. doi:10.1158/1538-7445.AM2014-3069
Absence of Dawn Phenomenon in Normal Children and Adolescents
Authors: Gabriela Marin, Susan R Rose, Maral Kibarian, Kevin Barnes, Fernando Cassorla
Journal: Diabetes Care (1988)

The dawn phenomenon consists of a rise in plasma glucose levels or insulin requirements in the early morning. This phenomenon has been observed in normal adults and in patients with diabetes mellitus. To determine whether this phenomenon also occurs in normal children and adolescents, we evaluated plasma glucose, insulin, C-peptide, and growth hormone levels during the early morning in 31 normal children between the ages of 8 and 18 yr. Blood samples were obtained through an indwelling catheter every 20 min for growth hormone and hourly for glucose, insulin, and C-peptide from 2100 to 0900 h. Glucose levels decreased slowly overnight from 2100 to 0900 h, despite increases in growth hormone levels. No significant rise in insulin or C-peptide levels was detected in the early morning in these normal subjects. There were no significant differences between prepubertal and pubertal children. We conclude that glucose, insulin, and C-peptide levels remain stable overnight, suggesting that the dawn phenomenon is not observed in normal children.
Short- and long-term efficacy of high-dose oral diltiazem for angina due to coronary artery disease: a placebo-controlled, randomized, double-blind crossover study.
Authors: M A Petru, M H Crawford, S G Sorensen, T K Chaudhuri, S Levine, R A O'Rourke
Journal: Circulation (1983)

The effects of oral diltiazem (360 mg/day) on exercise tolerance, left ventricular performance, and plasma lactate and catecholamine levels were studied in 13 patients with atherosclerotic coronary artery disease in a placebo-controlled, randomized, double-blind protocol. Exercise duration to the onset of ischemic ST segment depression, time to angina pectoris, and time to peak exercise improved by 120, 174, and 144 sec, respectively (p less than .0001). Left ventricular ejection fraction, as determined by radionuclide angiography, increased in patients at rest from 52 +/- 11% (mean +/- SD) during placebo therapy to 58 +/- 11% during diltiazem therapy (p less than .001); at peak exercise ejection fraction increased from 44 +/- 11% during placebo treatment to 52 +/- 15% during diltiazem therapy (p less than .01). The mean plasma norepinephrine level in patients at rest increased from 498 +/- 221 pg/ml during placebo treatment to 667 +/- 272 pg/ml during diltiazem therapy (p less than .05). Resting standing blood pressure and supine and standing diastolic blood pressures decreased significantly with diltiazem. In all 10 patients followed over a long term, oral diltiazem caused persistent improvement in exercise performance at 12 to 20 weeks, without evidence of placebo effects. Thus, diltiazem is highly effective in divided doses of 360 mg/day for the therapy of chronic angina pectoris due to coronary artery disease.
Merck pays $1bn penalty in relation to promotion of rofecoxib
Authors: J. H. Tanne
Journal: BMJ (2011)

The international drug firm Merck agreed with the US Department of Justice on 22 November to pay $950m (£615m; €720m) to resolve criminal and civil charges over the promotion and marketing of its painkiller rofecoxib (Vioxx).

In 2007 Merck paid $4.85bn to settle about 26 000 lawsuits relating to the drug in state and federal courts ( BMJ 2007;335:1011, doi:10.1136/bmj.39398.517176.DB).

The recent fines relate to a long Justice Department investigation of Merck’s promotion of rofecoxib. The funds will go to the US government and to the Medicaid federal insurance scheme for poor people, which paid for the drug under its programmes. Merck did not admit liability or wrongdoing but entered a corporate integrity agreement to strengthen the …
Work Disability and Workers' Compensation-Reply
Authors: Mitchell P. LaPlante
Journal: JAMA (1994)

<h3>In Reply.</h3> —In response to the<i>MMWR</i>report "Prevalence of Work Disability—United States, 1990," Dr Bohmfalk raises an interesting point about the possible influence of workers' compensation policy on the apparent decreasing trend in work disability in the United States. In the report we mentioned workers' compensation as one of several correlates identified in the literature that possibly contributed to the changes in work disability estimates. However, our purpose was not to elaborate on these correlates, and the quantification of the impact of workers' compensation on work disability trends was beyond the scope of the report. For the purpose of our analysis, we used the definition of work disability provided by the US Bureau of the Census (ie, the inability to perform work resulting from a physical, mental, or other health condition of 6 months' duration or longer). This inability included limitation in the type or amount of work performed
Pulmonary circulation and loss of microspheres from the lung following acute pulmonary venous occlusion
Authors: K. S ANDERSEN, L. SEGADAL
Journal: Cardiovascular Research (1981)

Journal Article Pulmonary circulation and loss of microspheres from the lung following acute pulmonary venous occlusion Get access KNUT S ANDERSEN, KNUT S ANDERSEN * From the Surgical Research Laboratory, Haukeland Hospital, University of Bergen, Norway *Address reprint requests to Dr Knut S Andersen, Surgical Department, N-5016 Haukeland Sykehus, Bergen, Norway. Search for other works by this author on: Oxford Academic PubMed Google Scholar LEIDULF SEGADAL LEIDULF SEGADAL From the Surgical Research Laboratory, Haukeland Hospital, University of Bergen, Norway Search for other works by this author on: Oxford Academic PubMed Google Scholar Cardiovascular Research, Volume 15, Issue 4, April 1981, Pages 233–238, https://doi.org/10.1093/cvr/15.4.233 Published: 01 April 1981
Editorial: Visits to China
Authors: H. H. Hussey
Journal: JAMA (1976)

For centuries, China was resistant, even impervious, to influences from the Western world. When communications were established, the United States made some notable contributions to Chinese medicine. One of the most remarkable was establishment, under a Rockefeller Foundation trust, of the magnificent medical school and hospital at Peking where many eminent US physicians taught and treated. After World War II, with the ousting of General and Madame Chiang Kai-shek's nationalist party by the communist forces of Mao Tse-tung and Chou En-lai, relations ceased between the newly established People's Republic of China and the United States. However, during recent years, exchanges between the two nations have been resumed and have begun with visits abroad by US physicians, who reported favorably on what they observed in the Far East. One of the most recent visits, to be reported in the<i>Archives of Internal Medicine</i>,<sup>1</sup>resulted in an astounding sequence of events.
Inappropriate hypergastrinaemia in asymptomatic healthy subjects infected with Helicobacter pylori.
Authors: J T Smith, R E Pounder, C U Nwokolo, S Lanzon-Miller, D G Evans, D Y Graham, D J Evans
Journal: Gut (1990)

An ELISA test determined serologically that eight of 95 apparently healthy men (aged 19-26 years) had an asymptomatic infection with Helicobacter pylori at the time of simultaneous measurement of 24 hour intragastric acidity and 24 hour plasma gastrin concentration. There was no significant difference in the median integrated 24 hour intragastric acidity between the H. pylori positive and H. pylori negative subjects (688 and 842 mmol/h/l; p = 0.271, respectively), whereas the median integrated 24 hour plasma gastrin concentration was significantly higher in the H pylori positive than in the H pylori negative subjects (389 and 198 pmol/h/l; p less than 0.001). Longterm hypergastrinaemia, associated with persistent H pylori infection, could be a cause of the increased parietal cell mass that is considered characteristic of duodenal ulcer patients.
The Use of Amino Acid Precursors in Nitrogen-Accumulation Diseases
Authors: John H. Close
Journal: New England Journal of Medicine (1974)

NITROGEN-accumulation diseases comprise chiefly chronic renal failure and portal–systemic encephalopathy. The major approach to treatment is preventive, resting on early diagnosis and measures to slow the progress of the disease. Present screening methods, however, do not reveal either renal or liver disease until about three fourths of the total parenchyma has been affected,1 , 2 so that early diagnosis is hampered unless new methods are developed.The annual death rate for renal failure is 15 per 100,000 — probably a conservative figure, since many nephritic deaths are ultimately classified under cardiovascular disease. Moreover, this rate has not improved in the past decade . . .
A randomized trial comparing primary angioplasty with a strategy of short-acting thrombolysis and immediate planned rescue angioplasty in acute myocardial infarction: the PACT trial
Authors: Allan M Ross, Karin S Coyne, Jonathan S Reiner, Samuel W Greenhouse, Cynthia Fink, Anthony Frey, Eduardo Moreyra, Mouhieddin Traboulsi, Normand Racine, Arthur L Riba, Mark A Thompson, Steven Rohrbeck, Conor F Lundergan
Journal: Journal of the American College of Cardiology (1999)
A Recombinant Modified Vaccinia Ankara Vaccine Encoding Epstein–Barr Virus (EBV) Target Antigens: A Phase I Trial in UK Patients with EBV-Positive Cancer
Authors: Graham S. Taylor, Hui Jia, Kevin Harrington, Lip Wai Lee, James Turner, Kristin Ladell, David A. Price, Manjit Tanday, Jen Matthews, Claudia Roberts, Ceri Edwards, Lesley McGuigan, Andrew Hartley, Steve Wilson, Edwin P. Hui, Anthony T. C. Chan, Alan B. Rickinson, Neil M. Steven
Journal: Clinical Cancer Research (2014)

Abstract Purpose: Epstein–Barr virus (EBV) is associated with several cancers in which the tumor cells express EBV antigens EBNA1 and LMP2. A therapeutic vaccine comprising a recombinant vaccinia virus, MVA-EL, was designed to boost immunity to these tumor antigens. A phase I trial was conducted to demonstrate the safety and immunogenicity of MVA-EL across a range of doses. Experimental Design: Sixteen patients in the United Kingdom (UK) with EBV-positive nasopharyngeal carcinoma (NPC) received three intradermal vaccinations of MVA-EL at 3-weekly intervals at dose levels between 5 × 107 and 5 × 108 plaque-forming units (pfu). Blood samples were taken at screening, after each vaccine cycle, and during the post-vaccination period. T-cell responses were measured using IFNγ ELISpot assays with overlapping EBNA1/LMP2 peptide mixes or HLA-matched epitope peptides. Polychromatic flow cytometry was used to characterize functionally responsive T-cell populations. Results: Vaccination was generally well tolerated. Immunity increased after vaccination to at least one antigen in 8 of 14 patients (7/14, EBNA1; 6/14, LMP2), including recognition of epitopes that vary between EBV strains associated with different ethnic groups. Immunophenotypic analysis revealed that vaccination induced differentiation and functional diversification of responsive T-cell populations specific for EBNA1 and LMP2 within the CD4 and CD8 compartments, respectively. Conclusions: MVA-EL is safe and immunogenic across diverse ethnicities and thus suitable for use in trials against different EBV-positive cancers globally as well as in South-East Asia where NPC is most common. The highest dose (5 × 108 pfu) is recommended for investigation in current phase IB and II trials. Clin Cancer Res; 20(19); 5009–22. ©2014 AACR.
ROENTGENOTHERAPY IN MEASURED MASSIVE DOSES
Authors: SIDNEY LANGE
Journal: JAMA (1913)

When I accepted the invitation to take part in the program of this section I planned to report some results of roentgenotherapy in massive doses in certain types of malignant conditions which had heretofore not only been refractory to roentgenotherapy, but also, because of their location and anatomic relation, had been regarded as unfavorable from the surgical point of view. I am unfortunately not able to make this report for two reasons: first, because the most of the cases under observation have not been under treatment long enough to warrant drawing conclusions, and secondly, because I am not sure that I have overcome certain obstacles in the technic of the administration of efficient irradiation of these cases. I shall therefore limit myself to some remarks on the measured massive dose. By efficient irradiation is meant the administration of a dose which will accomplish the desired result; of course, the desired
Clinical, genomic, and imaging predictors of myeloma progression from asymptomatic monoclonal gammopathies (SWOG S0120)
Authors: Madhav V. Dhodapkar, Rachael Sexton, Sarah Waheed, Saad Usmani, Xenofon Papanikolaou, Bijay Nair, Nathan Petty, John D. Shaughnessy, Antje Hoering, John Crowley, Robert Z. Orlowski, Bart Barlogie
Journal: Blood (2013)
The efficiency of transfusing high doses of platelets in hematologic patients with thrombocytopenia: results of a prospective, randomized, open, blinded end point (PROBE) study
Authors: Luc Sensebé, Bruno Giraudeau, Laurent Bardiaux, Eric Deconinck, Aline Schmidt, Marie-Laure Bidet, Catherine LeNiger, Elisabeth Hardy, Catherine Babault, Delphine Senecal
Journal: Blood (2004)
CYTOTOXIC EFFECTS OF SOME MINERAL DUSTS ON SYRIAN HAMSTER PERITONEAL MACROPHAGES
Authors: Elke Bey, J. S. Harington
Journal: The Journal of Experimental Medicine (1971)

Hamster peritoneal macrophages were grown in cell culture and their response to various conditions was examined. The cultures responded favorably to high concentrations of serum and to medium which had been preconditioned by contact with tumor cells. After 2–3 days of adaptation, they entered into a period of stability which lasted from the 4th to the 9th day. Macrophage cultures in this stable phase were treated with various samples of mineral dusts and their response determined by counting the number of viable macrophages/cm2 at intervals over a period of 72 hr. Crystalline silica Snowit was found to be nontoxic. Amorphous silica Fransil caused a characteristic cytotoxic effect and a rapid decline in cell population at doses less than 150 µg/5 x 105 cells. Of the three different kinds of asbestos used, chrysotile was toxic and amosite and crocidolite nontoxic at equivalent concentrations. A comparison of two preparations of chrysotile which differed in surface area showed that weight rather than surface area determines toxicity. Pretreatment of chrysotile with tryptose phosphate broth under drastic conditions accelerated but did not increase the final intensity of the cytotoxic effect.
Intercontinental House Call
Authors: Phil Gunby
Journal: JAMA (1999)

Our website uses cookies to enhance your experience. By continuing to use our site, or clicking "Continue," you are agreeing to our Cookie Policy | Continue JAMA HomeNew OnlineCurrent IssueFor Authors Publications JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry (1919-1959) Podcasts Clinical Reviews Editors' Summary Medical News Author Interviews More JN Learning / CMESubscribeJobsInstitutions / LibrariansReprints & Permissions Terms of Use | Privacy Policy | Accessibility Statement 2023 American Medical Association. All Rights Reserved Search All JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Forum Archive JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry Input Search Term Sign In Individual Sign In Sign inCreate an Account Access through your institution Sign In Purchase Options: Buy this article Rent this article Subscribe to the JAMA journal
Primary Biliary Cirrhosis and Liver Transplantation
Authors: E.Anthony Jones
Journal: New England Journal of Medicine (1982)

Primary biliary cirrhosis is a chronic liver disease of unknown cause that predominantly affects middleaged women.1 The syndrome of primary biliary cirrhosis arises as a consequence of a chronic nonsuppurative destructive cholangitis that involves the septal and larger interlobular bile ducts.2 The rate at which the bile-duct lesions evolve varies and is unpredictable. In asymptomatic patients the prognosis can be good (two decades), but once patients have symptoms attributable to the disease, its course is typically characterized by relentless destruction and loss of bile ducts, slowly progressive intrahepatic cholestasis, periportal piecemeal necrosis of hepatocytes, hepatic fibroplasia, and after a few . . .
Oral Anticoagulant Therapy During and After Coronary Angioplasty
Authors: Jurriën M. ten Berg, Barbara A. Hutten, Johannes C. Kelder, Freek W. A. Verheugt, H. W. Thijs Plokker
Journal: Circulation (2001)

Background —In the randomized Balloon Angioplasty and Anticoagulation Study (BAAS), the addition of oral anticoagulants to aspirin significantly reduced early and late events after coronary angioplasty. However, bleeding episodes were increased. The present report studied the intensity and the duration of anticoagulation as predictors of thrombotic and bleeding events. Methods and Results —A total of 530 patients, 34% of whom received a stent, were treated with aspirin plus coumarins. Half of the patients were randomized to angiographic follow-up. The target international normalized ratio (INR) was 2.1 to 4.8 during angioplasty and 6-month follow-up. Thrombotic events were death, myocardial infarction, target lesion revascularization, and thrombotic stroke. Bleeding complications were hemorrhagic stroke, major extracranial bleeding, and false aneurysm. “Optimal” anticoagulation was defined as an INR in the target range for at least 70% of the follow-up time. There were 17 early thrombotic events (3.2%), 7 early bleeding episodes (1.3%), and 10 false aneurysms (1.9%). The incidence rate for both early thrombotic and bleeding events was lowest in patients in the target range. A total of 61 late thrombotic events occurred (11.6%). Optimal anticoagulation was an independent predictor of late thrombotic events (relative risk, 0.33; 95% CI, 0.19 to 0.57) and was associated with a 0.21 mm (95% CI, 0.17 to 0.42) larger vessel lumen at 6 months. Late bleeding episodes (1.4%) were lowest in patients in the target range. Conclusions —Coumarins started before coronary angioplasty with a target INR of 2.1 to 4.8 led to the lowest procedural event rate, without an increase in bleeding episodes. During follow-up, optimal anticoagulation was associated with a decrease in the incidence of late events by 67% and a significant improvement in 6-month angiographic outcome.